Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin

Summary

Vitamin K antagonists (VKA) treatment starts with co-administration of low-molecular-weight heparin (LMWH). The anticoagulation induced by the two drugs is still not well determined. In the present study we used thrombin generation assay to evaluate the hypo-coagulation induced by treatment with VKA and by the combination of VKA with LMWH. Tissue factor triggered thrombin generation in platelet-poor plasma was assessed in samples from 15 healthy volunteers, 97 samples from patients treated with VKA and 41 samples from patients receiving enoxaparin and VKA. Patients were classified according to international normalised ratio (INR) level (<2, 2–3 and >3).In plasma samples from patients treated with VKA having INR 2–3 the inhibition of thrombin generation reached 50% compared to controls. In samples with INR>3 this inhibition was 80%. In samples from patients receiving both LMWH and VKA, thrombin generation was significantly decreased compared to the controls and VKA group. In samples with an INR 2–3 obtained from patients treated with LMWH and VKA, the inhibition of thrombin generation was similar to that observed in samples with an INR>3 obtained from VKA treated patients. Thrombin generation assay is sensitive to detect the global the anticoagulant effect produced by the association of LMWH and VKA. For equal INR dual anticoagulant treatment induces significantly more profound inhibition of thrombin generation compared to treatment with VKA alone. The clinical relevance of this observation merits to be studied in prospective studies in patients with defined indications of anticoagulant therapy.

Keywords

Oral anticoagulants - vitamin K antagonists - bridging treatment - LMWH - thrombin generation

• References

• 1 Ansell J, Hirsh J, Poller L. et al. The pharmacology and management of the vitamin K antagonists: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204S-33S.
• 2 Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004; 164: 1319-1326.
• 3 Spyropoulos AC, Turpie AG, Dunn AS. et al. REGIMEN Investigators. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 2006; 04: 1246-1252.
• 4 Ost D, Tepper J, Mihara H. et al. Duration of anticoagulation following venous thromboembolism: a metaanalysis. J Am Med Assoc 2005; 294: 706-715.
• 5 Deerhake JP, Merz JC, Cooper JV. et al. The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials. J Thromb Thrombolysis 2007; 23: 107-113.
• 6 Gerotziafas GT, Petropoulou AD, Verdy E. et al. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007; 05: 955-962.
• 7 Chantarangkul V, Clerici M, Bressi C. et al. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica 2003; 88: 547-554.
• 8 Hemker HC, Giesen PL, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
• 9 Gerotziafas GT, Depasse F, Busson J. et al. Towards a standardization of thrombin generation assessment: The influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay. Thromb J 2005; 03: 16.
• 10 Oake N, Fergusson A, Forster AJ. et al. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ 2007; 176: 1589-1594.
• 11 Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
• 12 Shculman S, Beyth RJ, Kearon C. et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 299S-3139S.
• 13 MacCallum PK, Rudnicka AR, Rumley A. et al. Low-intensity warfarin reduces thrombin generation and fibrin turnover, but not low-grade inflammation, in men at risk of myocardial infarction. Br J Haematol 2004; 127: 448-450.
• 14 Seljeflot I, Hurlen M, Arnesen H. Increased levels of soluble tissue factor during long-term treatment with warfarin in patients after an acute myocardial infarction. J Thromb Haemost 2004; 02: 726-730.
• 15 Takahashi H, Wada K, Satoh N. et al. Evaluation of oral anticoagulant therapy by measuring plasma prothrombin fragment 1 + 2. Blood Coagul Fibrinolysis 1993; 04: 435-439.
• 16 Furie KL, Rosenberg R, Thompson JL. et al. Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study. Neurology 2004; 63: 777-784.
• 17 Altman R, Scazziota A, Herrera L. et al. Relationship between thrombin generation and international normalized ratio in patients receiving oral vitamin K antagonist therapy. J Thromb Haemost 2007; 05: 1552-1569.
• 18 Gerotziafas GT, Bara L, Bloch MF. et al. Comparative effects of synthetic pentasaccharide, low molecular weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma. Bloo Coagul Fibrinol 1998; 09: 571-580.
• 19 Bendetowicz AV, Pacaud E, Béguin S. et al. On the relationship between molecular mass and anticoagulant activity in a low molecular weight heparin (enoxaparin). Thromb Haemost 1992; 67: 556-562.
• 20 Seligsohn U, Østerud B, Brown SF. et al. Activation of human factor VII in plasma and in purified systems. J Clin Invest 1979; 64: 1056-1065.
• 21 Eichinger S, Mannucci PM, Tradati F. et al. Determinants of plasma factor VIIa levels in humans. Blood 1995; 86: 3021-3025.
• 22 Radcliffe R, Nemerson Y. The activation of factor VII by activated factor X and thrombin. Isolation of a single chain form of factor VII. J Biol Chem 1975; 250: 388-395.
• 23 Dielis AW, Castoldi E, Spronk HM. et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 06: 125-131.
• 24 Alban S, Gastpar R. Plasma levels of total and free tissue factor pathway inhibitor as individual pharmacological parameters of various heparins. Thromb Haemost 2001; 85: 824-829.
• 25 Al Dieri R, Alban S, Béguin S. et al. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only party correlated to body weight. J Thromb Haemost 2006; 04: 83-89.
• 26 Konstantinidis K, Gerasimidis T, Verdy E. et al. Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood. Thromb Haemost 2007; 97: 109-118.
• 27 Gerotziafas GT, Depasse F, Chakroun T. et al. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in vitro clotting of whole blood and platelet rich plasma. Blood Coagul Fibrinol 2004; 15: 149-156.
• 28 Agnelli G, Verso M, Ageno W. et al. for the MASTER investigators. The MASTER registry on venous thromboembolism: Description of the study cohort. Thromb Res 2008; 121: 605-610.
• 29 Hyers TM, Spyropoulos AC. INNOVATE Investigators. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin. J Thromb Thrombolysis 2007; 24: 225-232.
• 30 LaPointe NM, Chen AY, Alexander KP. et al. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. Arch Intern Med 2007; 167: 1539-1544.